3 Stocks In Focus

Orthovita Inc. ( NASDAQ: VITA ) shares are soaring in today's trading. The
small cap stock reached a high of $2.82 in early trading, and at last check, it
was up 15.90% to $2.55, with volume up from daily average of 243,653 to 2.14
million. Orthovita shares have a 52-week range of $1.60-$4.68. Orthovita shares
are soaring after the company received a clearance from the FDA to market Vitoss
Bioactive Foam-2X Bone Graft Substitute in the U.S. Vitoss is used as
non-structural bone void filler in the spine, pelvis and extremities. Orthovita
is a Malvern, Pennsylvania-based specialty spine and orthopedic company. Pacer
International Inc. ( NASDAQ: PACR ) announced its fourth-quarter full year
financial results. The company reported fourth-quarter revenue of $373.3
million. The company's fourth-quarter net income fell by $10.4 million. It
reported a loss per share of $0.03 in the fourth quarter of 2010. For full year
2010 the company reported an increase of $224 million in its operating income.
Pacer International shares have a 52-week range of $2.74-$9.45. The stock is
currently trading below its 50-day and 200-day moving averages. Pacer
International shares gained 84.15% in the last one year. Pacer International is
a Concord, California-based asset-light North American transportation and
logistics services provider. Neurocrine Biosciences Inc. ( NASDAQ: NBIX ) shares
are soaring in today's trading. The small cap stock reached a high of $8.40 in
early trading, and at last check, it was up 9.60% to $8.05, with volume up from
daily average of 345,434 to 631,710. Neurocrine Biosciences shares have a
52-week range of $2.13-$9.30. Neurocrine Biosciences shares are soaring after
the company announced its fourth-quarter financial results. The company reported
fourth-quarter profit of $2.5 million, or $0.04 per share, compared with a loss
of $7.9 million, or $0.20 per share reported in the same period in the previous
year. The company reported fourth-quarter revenue of $13.7 million, up from
$740,000 reported for the same period in 2009. Neurocrine Biosciences is a San
Diego, California-based company, engaged in the development, discovery, and
commercialization of drugs for treatment of neurological and endocrine-related
diseases and disorders. This corporate profile is provided for information
purposes only and should not be used as the basis for any investment decision.
We are neither licensed nor qualified to provide investment advice. We were not
paid, nor do we hold a position in these stocks. We reserve the right to buy or
sell any stock mentioned in this report at any time after this post.